Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE InhibitorJOURNAL OF MEDICINAL CHEMISTRYIF6.82021-06-0314PREAI
Defining Target Engagement Required for Efficacy In Vivo at the Retinoic Acid Receptor-Related Orphan Receptor C2 (RORγt)JOURNAL OF MEDICINAL CHEMISTRYIF6.82021-04-144PRE
Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraintsBIOORGANIC & MEDICINAL CHEMISTRYIF32020-01-0113PREAI
Preparation and biological evaluation of conformationally constrained BACE1 inhibitorsBIOORGANIC & MEDICINAL CHEMISTRYIF32015-07-0116OAAI
Identification of Potent and Selective Hydantoin Inhibitors of Aggrecanase-1 and Aggrecanase-2 That Are Efficacious in Both Chemical and Surgical Models of OsteoarthritisJOURNAL OF MEDICINAL CHEMISTRYIF6.82014-12-0525PREAI
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft modelsINVESTIGATIONAL NEW DRUGSIF2.72012-12-29142OAAI